Christoph Seubert, MD

 

After completing a two-year fellowship in cardiac research funded by the American Heart Association, my research program has evolved to encompass three major areas: 1) clinically oriented anesthesia research, 2) neuronal effects of aromatic amino acids, and 3) drug design and development of novel drugs, including nanotechnology applications in medicine.

Clinically oriented anesthesia research. My major clinical research project addresses a question vital to the medical care of astronauts, namely how adaptation to weightlessness changes the response to general anesthesia. For this NASA-funded endeavor, I have assembled an intercollegiate research team from the Department of Anesthesiology, the College of Pharmacy, and the College of Allied Health Professions to study the changes in pharmacokinetics, drug effect, and recovery from anesthesia in a randomized cross-over study of volunteers exposed to an earth-based simulation of weightlessness. A recent new clinical research direction is the study of effects of anesthesia on long-term mortality in a cohort of women undergoing surgery for gynecologic tumors.

Neuronal effects of aromatic amino acids. Although phenylketonuria is the most frequent biochemical cause of mental retardation and is a well-researched prototypical genetic disease, the pathogenesis of its neurological symptoms is poorly understood. In close collaboration with Dr. Martynyuk, we have described the neuronal effects of L-phenylalanine, the pathogenetic agent of phenylketonuria. These studies span cellular electrophysiology in neuronal cultures and brain slices, receptor pharmacology, mass spectrometry, molecular biology, and whole animal studies in the genetic mouse model of phenylketonuria. Because of robust results across various experimental settings, we plan to take these studies from bench to bedside in the form of a pilot study in phenylketonuria patients, which is already approved and supported by the NIH-funded General Clinical Research Center. Further directions of this research effort have focused on neuroprotective, neuro-modulatory and anti-epileptic effects of aromatic amino acids.

1: Martynyuk AE, Glushakov AV, Sumners C, Laipis PJ, Dennis DM, Seubert CN.
  Impaired glutamatergic synaptic transmission in the PKU brain.
Mol Genet Metab. 2005 Dec;86 Suppl 1:S34-42. Epub 2005 Sep 8. Review.
2: Bajpai L, Varshney M, Seubert CN, Stevens SM Jr, Johnson JV, Yost RA, Dennis DM.
  Mass spectral fragmentation of the intravenous anesthetic propofol and structurally related phenols.
J Am Soc Mass Spectrom. 2005 Jun;16(6):814-24. Epub 2005 Mar 24.
3: Yarotskyy V, Glushakov AV, Sumners C, Gravenstein N, Dennis DM, Seubert CN, Martynyuk AE.
  Differential modulation of glutamatergic transmission by 3,5-dibromo-L-phenylalanine.
Mol Pharmacol. 2005 May;67(5):1648-54. Epub 2005 Feb 1.
4: Glushakov AV, Glushakova O, Varshney M, Bajpai LK, Sumners C, Laipis PJ, Embury JE, Baker SP, Otero DH, Dennis DM, Seubert CN, Martynyuk AE.
  Long-term changes in glutamatergic synaptic transmission in phenylketonuria.
Brain. 2005 Feb;128(Pt 2):300-7. Epub 2005 Jan 5.
5: Ozcan MS, Praetel C, Bhatti MT, Gravenstein N, Mahla ME, Seubert CN.
  The effect of body inclination during prone positioning on intraocular pressure in awake volunteers: a comparison of two operating tables.
Anesth Analg. 2004 Oct;99(4):1152-8, table of contents.

Department Patents

GAARRC

Faculty Research


Nikolaus Gravenstein, MD
Department Chair

Michael J Banner PhD
Jerry Berger, MD
Larry Berman, MD
Azra Bihorac, MD
David Bjoraker, MD
Don Caton, MD
Laurie K Davies, MD
Donn Dennis, MD
F Kayser Enneking, MD
Tammy Euliano, MD
Andrea Gabrielli, MD
Dietrich Gravenstein, MD
Joachim S Gravenstein, MD
Gregory M Jenelle, MD
Sem Lampotang, PhD
A Joseph Layon, MD
Emilio Lobato, MD
Michael E Mahla, MD
Anatoly Martynyuk, MD
Richard J Melker, MD
Jerome Modell, MD
Tim Morey, MD
David A Paulus, MD
Yong Gang Peng, MD
Raymond Schultetus, MD
Christoph Seubert, MD
Avner Sidi, MD
Cheri Sulek, MD
Hans van Oostrom, PhD